Model Parameters for PrEP Scenarios.

HIV disease progression [4] was assumed the same for drug-resistant and drug-sensitive virus because: i) a temporary predominance of drug-resistant mutants was assumed in the model; and ii) though lower viremia has been observed in the experimental setting [14], it is unknown whether PrEP would attenuate the course of HIV infection.
HIV infectivity and disease progression [4] in individuals with drug-sensitive virus were assumed to be unchanged by their PrEP status.
*Relative to infectivity (per sex act probability of transmission) of donor with wild-type virus based on stage of infection, γΩ[4].
†Latin Hypercube Sampling (uniform distribution).